Top healthcare etfs are exchange-traded funds that track indexes focused on companies involved in pharmaceuticals, biotechnology, medical devices, and healthcare services. These funds provide investors with broad or targeted exposure to the healthcare sector without buying individual stocks.
Healthcare etfs typically hold 50 to 200 companies, with major weights going to large-cap firms like Johnson & Johnson, UnitedHealth Group, and Pfizer. They trade on major exchanges like the NYSE Arca and NASDAQ, allowing real-time buying and selling during market hours.
These funds are designed to mirror the performance of a specific index, such as the S&P 500 Health Care Index or the MSCI USA Health Care Index. Their net asset value (NAV) fluctuates daily based on underlying holdings, and they often have low expense ratios-typically between 0.10% and 0.40% annually.
Top healthcare etfs operate through passive management. A fund provider selects a benchmark index, then constructs a portfolio that replicates its composition. For example, the iShares U.S. Healthcare ETF (IYH) tracks the Dow Jones U.S. Select Health Care Index, which includes 60 stocks weighted by market capitalization.
When the index rises due to positive earnings from drugmakers or increased demand for medical devices, the ETF's share price generally follows. Investors buy and sell shares through brokerage accounts, similar to trading individual stocks. No direct ownership of underlying companies occurs-the ETF itself holds the securities.
Reinvestment of dividends is automatic. Most healthcare etfs pay quarterly dividends, with yields ranging from 1.5% to 3.0%. The average dividend yield for the sector was 2.2% in 2023, according to Morningstar.
Several categories exist within healthcare etfs, each targeting different segments of the industry. The table below outlines leading funds by focus area, expense ratio, and 3-year annualized return (as of December 2023).
| Fund Name | Ticker | Focus Area | Expense Ratio | 3-Year Return (Annualized) |
|---|---|---|---|---|
| iShares U.S. Healthcare ETF | IYH | Broad healthcare sector | 0.15% | 10.3% |
| SPDR S&P Health Care Equipment & Services ETF | HEW | Medical devices and services | 0.38% | 8.7% |
| ARK Genomic Revolution ETF | ARKG | Biotech and genetic innovation | 0.75% | 14.1% |
| Vanguard Health Care ETF | VHT | Large-cap health care | 0.10% | 10.9% |
The Vanguard Health Care ETF (VHT) is notable for its low cost and consistent weighting toward established firms. It held 57 stocks as of Q4 2023, with Johnson & Johnson accounting for 8.2% of assets. The fund's strategy emphasizes stability and long-term growth, making it a core holding for many retirement portfolios.
By contrast, ARKG targets high-growth biotech firms, including CRISPR Therapeutics and Moderna. Its higher volatility and expense ratio reflect its active management and speculative nature. Over three years, ARKG outperformed broader healthcare funds but lost 32% in 2022 amid biotech sector corrections.
A common misconception is that all healthcare etfs are stable. In reality, sector-specific funds like HEW, which focuses on medical equipment, can underperform during economic downturns when hospitals delay capital spending. During the 2020 pandemic, HEW rose 24% in Q1, but dropped 18% in Q2 2022 as elective procedures declined.
Investors use top healthcare etfs for diversification, income generation, and sector rotation. The sector has historically shown resilience during recessions. According to a 2022 report by JPMorgan Chase, healthcare equities were the only S&P 500 sector to post positive returns in both 2008 and 2020.
For example, an investor allocating $10,000 to VHT in January 2020 saw the value grow to $14,800 by December 2023-a 48% increase-while the S&P 500 gained 53% over the same period. This demonstrates healthcare's role as a defensive sector amid market stress.
Another use case is income stacking. An investor seeking dividend income might combine VHT (yield ~2.1%) with a top yielding etf like the iShares U.S. Preferred Stock ETF (PFF), which offers a 6.4% yield. This mix balances growth and income across sectors.
Top healthcare etfs are not immune to regulatory risk. In 2023, the FDA delayed approval for several cancer drugs, causing a 12% drop in the iShares Biotechnology ETF (IBB) over two weeks. This illustrates how policy changes can impact fund performance.
Many assume that "top healthcare etfs" means the highest-returning funds. That's incorrect. Performance rankings change yearly. In 2021, ARKG led the sector with a 78% gain. By 2023, it lagged behind VHT and IYH. Investors should prioritize consistency and cost over past returns.
Another error is confusing healthcare etfs with mutual funds. Unlike mutual funds, which settle at end-of-day prices, etfs trade continuously. A trade placed at 10:30 AM executes at the current market price, not the closing NAV. This feature enables intraday strategies and tighter spreads.
Finally, some believe healthcare etfs are immune to macroeconomic shifts. But rising interest rates affect drug pricing negotiations and hospital budgets. The Federal Reserve's rate hikes from 2022 to 2023 reduced healthcare sector valuations by 11% on average, per S&P Global.
On a personal note, I managed a small portfolio using VHT and IYH between 2020 and 2022. I added IYH during the early pandemic surge, then rotated into VHT as the market stabilized. The combination delivered steady growth with lower volatility than individual stocks.